#tian caron

[ominous-feychild]

[the following is an excerpt of an exchange between: Kieran Caron and an unnamed noble]

(context: following a meeting between Caron and some nobility, a certain struggling Noble waits for the other conversations end—and everyone else to leave—so they can approach Caron...)

Noble: (tentatively) “So, I've been meaning to ask...”

Caron: [turns to them with his arms crossed, quirking an eyebrow]

Caron: [loosening his crossed arms, evenly) “Yes?”

Noble: (still tentatively) “Your son—”

Caron: [face quickly empties, his eyes subtly narrowing on them]

Noble: “—Sebastián, was it?”

Caron: [arms dropping from their crossed position, instead puts his knuckles on his hips as he watches them carefully]

Caron: [grudgingly] “... that is one of them, yes.”

Noble: [taking the hint, awkwardly) “Right, sorry, I didn't mean anything about your other son. I just meant—he, Sebastián, graduated from your school, right?”

Caron: [watching them carefully, voice even) “Correct.”

Caron: [would say more, but—]

Noble: [interrupts, faux-pleasantly) “That's what I thought! But, you know, I never heard if he swore himself into a knightage. Did he?”

Caron: [restraining his anger, instead offers the slightest of bitter, smug smiles]

Caron: (a hint of amusement slipping into his voice) “No. If I recall correctly, he thought himself better than that, and didn't wish to, I believe, 'sell out' to anyone who might 'waste his talents'.”

Noble: [stunned speechless—]

Noble: [struggling for words, especially because they aren't sure whether or not they can bash Tián for his 'arrogance and selfishness']

Caron: [lip twitching slightly as he fights a smug grin, quirks an eyebrow at Noble]

Caron: (a hint of his amusement in his voice; matter-of-factly) “I think he's right.”

Noble:

Noble: [stunned, blurts) “I'm... sorry?”

Caron: (without hesitation, matter-of-factly) “I said 'I think he's right'. He's much too good to waste his time attending to other, selfish nobles who think they're worthy of an ounce of his attention. Don't you agree?”

Caron: [can't help the slight, dark smile as he meets their eyes]

Noble: [stunned silent again]

Noble: [... but quickly forces a pained laugh and smile]

Noble: (awkwardly) “Of course. I'm sure your son is one of the greatest to come out of your school, Sir.”

Caron: [dark smile growing a bit wider, but nods solemnly]

Caron: (unable to keep his amusement from his voice) “Yes, Tián is one of the best. In every way. But of course I'd think that...” [pointedly quirks his eyebrows] “I'm his father.”

Caron: [face emptying, steps forward as though to walk past them] “Regardless.”

Caron: [pauses walking to place his hand on Noble's shoulder, meeting their eyes with his eyebrows quirked]

Caron: (matter-of-factly) “Good talk.”

Caron: [doesn't wait for a response. Drops his hand from their shoulder and moves past to leave]

Caron: [not bothering to look at them until he reaches the door; speaking generously all the while) “Have a good one. Good luck in your endeavor finding a knight.”

Caron: [pauses, looking back to them and giving a fraction of a second for a response—]

Noble: [too stunned—]

Caron: [and out!]

Noble: [passes out]

@honeybewrites @the-golden-comet @illarian-rambling @ashirisu @urnumber1star

@the-letterbox-archives @48lexr @aalinaaaaaa @thecomfywriter @an-indecisive-nerd

@seastarblue @leahnardo-da-veggie @world-of-iridensia

Banners from @saradika

[444namesplus]

Afria̍t Alakkalame Albanduntåg Altel Ambour Amelas Arata Arimost Ayili Azere Azerrovaṇṭi Aṭaromaṭar Bahiá Banesto Bantong Basút Beleterse Belsh Bokor Boutche Bream Burking Caron Carthi Catalmyk Cater Cedish Cehëlame Cehëlanian Cerenbahník Chehëla Ciani Cians Cjava Clatan Clayeishawa Coakkaʻah Coatige Comalatl Comonacey Crelisian Crian Crombo Cugue Cyrgyz Cyrian Czerbydrea Cʼersolchi Daabai Daakha Donian Dukir Dutchern Dutchi Duthi Easse Elaravagāṛī Eletrai Elgagba Etalian Etoṭarian Faino Farisilwaii Fayalia Finyn Flechē Flemboio Flesian Fleståg Flestíche Fletern Frens Fretrabi Frian Frianiandi Frilchhi Gaeindut Gagāḍī Gareter Garian Garimi Garth Garusyn Geoli Grelada Hakik Hectrau Hersian Hianese Hileta Hojcens Hojâs Hortshkor Hosagong Hoshko Htoṭarimi Htéenban Htéens Huatly Hurkikur Hurkmeni Husyn Huǒchojcelu Idagersk Idjazeraki Idonesii Ilassage Ilasút Indinorel Inorman Irgâḍay Irianian Irjibelisha Iseterse Ishko Ishta Ishto Itajo Ithiá Jabasha Japan Jinorinha Junde Junjanian Kacey Kaijavajno Kalanian Katino Khalamese Kkaal Kkaivajizd Kkaʻahník Kolemish Kotalia Kurkish Kuyezd Kyrici Kāʻaan Kōccia Kōccifer Kōcciferbok Kōccit Kˀą́samen Laorse Laortu Lassh Lawah Lianian Licherai Linyno Lodew Loksha Lotaray Lottia Lovaṇṭi Lovet Luxem Macedisha Machche Macʿkʿ Malese Mannau Maxassi Maxosh Mayillis Maṭarelug Maṭaric Melsh Mensiankan Merskoric Milech Mirish Mogiṭār Mokmål Moksh Mokshtą Monesey Mongon Moojâs Moorthi Morgian Morgypt Morian Morsil Moshaltea Moshaw Mánia Mánic Mázaz Nachuvak Ngolcienese Ngulu Norew Norgalantåg Norsian Nynorgyzni Nāiňtug Occifer Ocifei Ociąg Odfay Onterajo Osami Osvassii Otarian Oðíht Oðíhtan Pashkolch Patelgalija Patheh Pereek Perenban Perla Pocien Poestibela Poiyal Polesepoz Poliani Porni Poyeoree Poyid Poyrgeľ Pozcombo Ptiante Ptimelvet Pujarian Pukai Pukazersian Punahník Pundene Purika Pójer Pójibek Pójinys Qaterai Qatian Qatigaṛi Qatogiṭār Qithian Qîtan Raban Rabic Raijava Rakuyghtą Ranian Ratic Ratvijapi Rebre Reinan Rembo Reneseni Renia Renia̍t Roakhmenden Roaki Roatār Romal Romokmese Rovagāḍī Runahník Rungon Rusagāḍī Russam Ryezd Rótjabichē Rótjapan Saapa Sagiṭār Samal Satan Sathi Scoat Scoman Scomboio Sepurmelam Serpoyil Shkin Shkish Shtorwe Siangonica Sicat Silia Silinam Silièchi Sillitār Skotan Slovash Solch Soliji Solturing Songu Sontu Soutcha Squese Sraijapi Sraivagan Srathi Sraukingia Srika Sturimorian Svageolian Swedon Swelinhaz Swesey Tajno Tamese Tarain Tarik Tarpaan Tatal Teamelas Techē Tehëlan Tepuja Terbo Terbok Terbydre Tergi Terlia Terni Terse Teëpchhi Teëpchiluhy Teëpchē Therbydren Thuōi Tiane Tighuǒchhâ Tishtéeni Toatar Tokodstíchi Tokorse Toksh Torgian Toṭar Trabout Traeiz Traiiani Trainga Traiya Trakʼ Tralo Tramelasút Trandu Trane Tranisha Trean Treigring Trela Trelsh Trenian Treto Triand Trigagāḍī Trilectr Trimeash Trinnian Triulu Trèannic Tshazakik Tshtą Tsugu Tsíime Tsíimesetam Tujăs Turdinha Turge Turkmål Tëntechē Tëntoatl Tëntok Tëntonesey Tëntu Tëntåg Tëpche Tūmanda Tẽrean Tẽren Tẽrennan Uferabi Uferme Uguanespasq Ukaabouyghu Ukaing Unanan Undeferbast Urdian Urdung Urduthi Uyghtoṭar Uzbei Uzbelgaḍḍī Vagianishar Vagāṛī Vaṇṭi Vians Vlaorsk Vongan Vonianatam Vozcoake Wahník Wegianah Wegitār Wegiṭār Wegyptian Welgal Yeottin Yilin Yiral Yucarali Yucataapa Zazirilu Začhara Zhuese Zhusami Zhuvaṇṭi Zilugue Ziraboio Zirabur Zirath Zirgian Zirimerse Zirjikan Zucalodfari Zuchecher Zuchingaro Zulind Āgagaṛi Āgalane Āgalmyk Āgaṛi Āggāṛī Ğataanavóz Ğatermest Ğatigaelam Ğatlitagāṛī Ğatār Ğbaan Ğbabo Želanisinha Želaorgit Želatage Želestesti Želgaḍḍī

[444names]

american forenames, surnames and states + chinese cities + periodic table elements

Acobalder Acobally Adriet Adriquez Aguirrett Almers Almes Alsh Alton Anders Andez Angfang Angying Anneth Anton Aprin Ariamusse Arlos Artz Ayang Baili Bair Baldinan Baltay Baoto Bari Bartiz Beil Beili Beina Bent Benter Bert Bette Billiotte Blacruz Blandian Blang Bobb Bowe Bozhuaying Bradshand Branda Brantimoth Brenee Brenqiu Brera Burges Cadownsen Calleroach Cami Candry Candy Cangyi Cangzhong Carleshan Carne Carold Caron Carongrace Carvins Casteve Castine Cathangge Chael Chanjiang Cheng Chongxiang Chrium Chroe Clain Clard Claurie Cleah Cock Collouglas Conne Cons Consteng Cookes Cooks Courichoa Cray Cristi Cristy Cruzhou Cummin Cunnie Dalazquez Dangshui Danium Danjian Darry Datoyang Daven Deron Diany Ding Dong Dongcher Dore Dorenhe Doughn Douglances Duanie Dujilium Dyers Ebonne Eleah Elin Elliveron Erium Esteeler Esterines Etha Europinoz Evan Evedo Florina Foshala Frandley Frandra Frandy Fudith Fuqi Fuquanwei Fuyanjian Fuzhondace Garia Gejin Genevanedy Gininggang Gins Glore Gomero Gomers Gong Gongkou Gongqiu Gongyingel Gonzaler Goodmantes Gramonard Grosa Guisiang Guthdakota Guzmandra Halas Hang Hangde Hangdu Harien Hartz Hatt Heathryn Heathy Hega Heid Hestine Hichong Hobbins Holina Hong Honglaibin Hoper Howendy Howers Huana Huang Huangzhou Hughn Hulton Huntes Indy Iridgers Jacquez Jamentium Janes Jare Jarez Jess Jiana Jiannes Jiaobersen Jiaogang Jieshi Jiliamsey Jing Jisheidi Jodingguan Johnstana Jone Joses Juliu Juropium Kangyann Kanshuluna Karez Kathristy Katine Kell Kendersey Kentium Kurtney Laird Lamber Land Laney Lard Lechnett Lelandra Lelinhot Leod Lian Liangyuana Licha Lina Lingde Livas Lone Loree Lowen Lucilina Lushang Lüliandy Mach Magnes Marginan Mariel Mariong Marizhou Marla Marson Marsong Marvis Massa Matti Mcca Mcconwayne Mccraig Mcdan Mcfarr Mcgowayne Mcguirret Mclemarvin Mcmileshi Meador Medinguyen Meishorthy Meith Meitney Miang Miangang Micharla Midt Millman Mily Mire Misti Mond Monradshan Mont Moradley Morester Morsey Muel Muelin Mull Murrantha Nancheng Nand Nandrews Nebra Nice Nielice Ning Ningzhou Nitron Northance Olla Orrolynne Owers Pacholton Padium Palmeryl Panji Patt Patthelson Pauletium Pennis Peterbing Phia Ping Pingel Pingluori Pitt Port Pott Prin Pruichan Qianyunfu Qiaoya Qiaozhou Racey Racia Rady Raqu Reen Rence Rencer Robeith Robers Robertha Roberty Roble Rodge Rodner Rome Rosium Rown Rubidi Ruijian Ruila Rushu Sala Sama Samara Samartez Sampton Sanchen Sanmen Sansas Santu Sarie Schris Schward Selencia Sell Serris Serrishou Setta Shan Shanum Shaogan Shel Shelendy Shelps Shenja Sheparks Shepparks Sher Sherika Shui Shuiz Skins Sopherd Southryn Spencias Statine Stengfang Ster Sterson Stes String Strogentes Stroger Strongang Suixing Swanya Sylvin Sylving Taiyang Tamie Tang Tash Ters Terson Thangchoa Thong Tian Tiannie Tierceliao Timo Tong Trickerson Vanise Velack Vernadium Vers Vila Violandy Viole Viviang Vivingyang Wadela Wadett Walla Wates Watkinson Wattie Weaves Webbie Weller Wheeleona Whitner Wiggs Wight Wilker Will Willene Willo Wilsonia Wischmidd Wisco Woodymium Wudan Wugaoanna Wuweifang Wyater Wynner Wyoming Wyorkman Xing Xingkou Yibinzhou Yicharon Yichelead Yichmony Ying Yola Yons Zachaniel Zamon Zaozhou Zhana Zhanglaine Zhaoyang Zhou Zhuan Zhumphrey Zircon Ziyangzi Zunyi Zunyu

same thing but with lesser order

Alde Alillinne Alis Amarsott Amon Analvidne Angzhuzhou Ante Arading Aray Arca Ardium Arotomers Arren Ater Bairis Balleatin Bard Barner Barricky Barroe Baunlas Beang Bein Bellilcia Belly Bernan Blarrer Blatephi Bohnson Boods Bordox Boto Branie Brengtand Brez Brie Bron Cadia Calinie Calt Camen Canatt Cang Card Cark Carlas Carry Cart Casa Cashens Cecker Changgill Chansong Cheleahou Cherbi Cherley Chou Chri Chua Clail Clang Clangdey Clashiniff Cleett Cles Clexance Clung Conieliang Coton Dalle Dartiam Dawnio Dayler Daynchen Deart Dertro Dery Destin Dilium Ditan Dium Doline Doll Dong Dongzhou Dorgins Dreng Dridinorta Dung Dunhujim Durrent Edge Eshota Eulanne Fanew Fang Farcarli Faurtnes Feitchard Fenroody Ferks Ferricare Finet Fiteve Foriquer Fortry Frannin Fuyuz Gaberriss Galey Gashiterry Gileen Gillen Ging Gium Golore Gominard Gooke Gookley Gradia Gricixon Guan Guez Guiz Guton Guyannorna Guytt Guyueqium Haft Halaikou Hally Hamb Hamer Hamillace Hana Handerett Hang Hanmenrie Hanyang Haoyi Hard Harks Harle Heang Hejie Held Helia Hell Hened Hens Henta Hepadrowen Hirgola Hoanger Hong Huadium Huan Huang Hullamel Huozacart Ianeyer Ilen Illetthis Inxillon Jacdaker Jachurent Jacks Jearish Jeatkie Jengen Jennart Jermong Jerna Jers Jiana Jiang Jimars Jinance Jindron Jing Jinghose Jinsonerna Jiyatrice Joedet Jong Jorriston Jossimer Joydris Kainza Kaiwu Kang Kanobard Karisonium Karmard Karvent Kath Katt Kauez Kell Khou Kievarster Kinxin Krick Krielaing Krielci Lairbingxi Lancha Lankottsyl Lanyuzhuan Laoyan Lempshui Leng Lenzhon Lerincy Lhobsotona Lian Liangtan Licaroe Licheng Ling Lingbaoyan Liniummy Lium Liviretes Llie Llium Locheph Lont Lord Lorklandan Lortnewson Loweng Loyangshui Luchanqium Mabill Maley Manjium Mannearver Many Manzhou Markson Marle Masquang Mathyde Maxin Maxing Mayan Mccars Mcco Mcdosh Mcger Mcks Mcla Mclasmaro Mclen Mcliu Megolairms Meiff Melinsim Menan Meng Merbel Merey Meroseang Mill Mine Miney Ming Minie Mium Mongzhouss Monrin Moodium Mormanium Mormsopar Mosboodia Muez Muland Mulinie Mura Murpeter Murs Myron Ninerninie Niqueqidi Niupe Nowayon Nyuan Obbye Odinie Open Orris Osbynnium Pald Parce Parsetterr Pathaing Patranthon Pearinsone Pella Penei Penson Piermatt Pine Plut Poling Pophiferno Potenie Prushi Qing Qitere Qium Quez Racklagam Radford Radi Rang Razibensy Regio Relilan Reling Rhou Rillose Rindong Ring Risenshun Rocond Rodaledey Rodo Roleinathi Roney Rong Rony Rosbon Roseandre Rubers Ruzmaney Sart Sena Seping Shaiyathy Shamps Shan Shandy Shang Shas Shay Shen Shencia Shou Shuang Shuo Siefengjia Sium Skan Slovancas Smium Sodre Song Soning Sont Soscon Spelia Stes Stick Stie Stiz Ston Suilley Suquez Susa Sushan Susuzher Suzhann Syler Tandy Tangyant Tattilmolf Tharr Thespen Timoner Ting Tins Todo Tonine Trudia Truzhou Tundsond Tyroll Ulle Urse Valengin Vark Vaudelanum Vene Venzhou Vercuss Vers Vian Vicarethiz Videass Vinna Vise Wanahen Warter Water Wattriling Waynores Weatkina Weers Weidna Weith Whena Wher Will Wine Wisha With Wucken Wuytterson Wuzmark Xiane Xicey Xicur Xinanzhord Xinding Xing Xinor Yant Yicha Ying Yizher Yonarce Ytua Zhan Zhang Zheze Zhom Zhon Zhou Zhund Zimmongs Zird

[treatingeatingdisorders]

Eating Disorder Healing Through Experiential Therapy: Psychodrama and Sociometry

Tian Dayton, MA, Ph.D., T.E.P hosted a webinar on Psychodrama and Sociometry and Eating Disorder Healing.

p { margin-bottom: 0.25cm; line-height: 120%; }a:link { }

For More information on treating Eating Disorders, please contact Remuda Ranch at The Meadows.

Tian Dayton, MA, Ph.D., T.E.P is the director of The New York Psychodrama Training Institute where she runs training groups in psychodrama, sociometry and experiential group therapy. She served as Caron’s director of program development for eight years and Breathe’s for four. She was also a professor at NYU for eight years teaching psychodrama and currently sits on the Scientific Advisory Board for the National Association for Children of Alcoholics (NACoA). She is a fellow of the American Society of Psychodrama, Sociometry and Group Psychotherapy (ASGPP), and is the winner of their scholar’s award and the President’s award. She has served as Editor in Chief of the Journal of Psychodrama, Sociometry and Group Psychotherapy for ten years and as an executive editor for eight, she sits on the professional standards committee. She is also the winner of The Mona Mansell Award and The Ackermann Black Award for her contributions to the field of addiction.

You can view the full 18-minute presentation on YouTube.

Content Source

[naivelocus]

Biased signalling: from simple switches to allosteric microprocessors

1.

Lagerstrom, M. C. & Schioth, H. B. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov. 7, 339–357 (2008).

2.

Luttrell, L. M., Maudsley, S. & Bohn, L. M. Fulfilling the promise of “biased” G protein-coupled receptor agonism. Mol. Pharmacol. 88, 579–588 (2015).

3.

Santos, R. et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov. 16, 19–34 (2017).

4.

Smith, J. S. & Rajagopal, S. The β-arrestins: multifunctional regulators of G protein-coupled receptors. J. Biol Chem. 291, 8969–8977 (2016).

5.

Benovic, J. L., Strasser, R. H., Caron, M. G. & Lefkowitz, R. J. β-Adrenergic receptor kinase: identification of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor. Proc. Natl Acad. Sci. USA 83, 2797–2801 (1986).

6.

Lohse, M. J., Benovic, J. L., Codina, J., Caron, M. G. & Lefkowitz, R. J. β-Arrestin: a protein that regulates β-adrenergic receptor function. Science 248, 1547–1550 (1990).

7.

Goodman, O. B. Jr et al. β-Arrestin acts as a clathrin adaptor in endocytosis of the β2-adrenergic receptor. Nature 383, 447–450 (1996).

8.

Oakley, R. H., Laporte, S. A., Holt, J. A., Barak, L. S. & Caron, M. G. Association of β-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. J. Biol Chem. 274, 32248–32257 (1999).

9.

Laporte, S. A., Oakley, R. H., Holt, J. A., Barak, L. S. & Caron, M. G. The interaction of β-arrestin with the AP-2 adaptor is required for the clustering of β2-adrenergic receptor into clathrin-coated pits. J. Biol Chem. 275, 23120–23126 (2000). References 7–9 are seminal papers describing the role of β-arrestin in GPCR endocytosis.

10.

Hanyaloglu, A. C. & von Zastrow, M. Regulation of GPCRs by endocytic membrane trafficking and its potential implications. Annu. Rev. Pharmacol. Toxicol. 48, 537–568 (2008).

11.

Gao, H. et al. Identification of β-arrestin2 as a G protein-coupled receptor-stimulated regulator of NF-κB pathways. Mol. Cell 14, 303–317 (2004).

12.

Shenoy, S. K. et al. β-Arrestin-dependent, G protein-independent ERK1/2 activation by the β2 adrenergic receptor. J. Biol Chem. 281, 1261–1273 (2006).

13.

Beaulieu, J. M. et al. An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122, 261–273 (2005).

14.

Luttrell, L. M. et al. β-Arrestin-dependent formation of β2 adrenergic receptor-Src protein kinase complexes. Science 283, 655–661 (1999). This is one of the first studies describing the signalling functions of β-arrestins.

15.

Ahn, S., Kim, J., Hara, M. R., Ren, X. R. & Lefkowitz, R. J. β-Arrestin-2 mediates anti-apoptotic signaling through regulation of BAD phosphorylation. J. Biol Chem. 284, 8855–8865 (2009).

16.

Kendall, R. T. et al. Arrestin-dependent angiotensin AT1 receptor signaling regulates Akt and mTor-mediated protein synthesis. J. Biol Chem. 289, 26155–26166 (2014).

17.

Eichel, K., Jullie, D. & von Zastrow, M. β-Arrestin drives MAP kinase signalling from clathrin-coated structures after GPCR dissociation. Nat. Cell Biol. 18, 303–310 (2016).

18.

Coffa, S., Breitman, M., Spiller, B. W. & Gurevich, V. V. A single mutation in arrestin-2 prevents ERK1/2 activation by reducing c-Raf1 binding. Biochemistry 50, 6951–6958 (2011).

19.

Ferrandon, S. et al. Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. Nat. Chem. Biol. 5, 734–742 (2009).

20.

Calebiro, D. et al. Persistent cAMP-signals triggered by internalized G-protein-coupled receptors. PLoS Biol. 7, e1000172 (2009).

21.

Irannejad, R. et al. Conformational biosensors reveal GPCR signalling from endosomes. Nature 495, 534–538 (2013). References 19–21 are impactful studies demonstrating sustained G protein signalling from endosomes following endocytosis regulated by β-arrestins.

22.

Roth, B. L. & Chuang, D. M. Multiple mechanisms of serotonergic signal transduction. Life Sci. 41, 1051–1064 (1987).

23.

Luttrell, L. M. Minireview: More than just a hammer: ligand “bias” and pharmaceutical discovery. Mol. Endocrinol. 28, 281–294 (2014).

24.

Jarpe, M. B. et al. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]Substance P acts as a biased agonist toward neuropeptide and chemokine receptors. J. Biol Chem. 273, 3097–3104 (1998).

25.

Urban, J. D. et al. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320, 1–13 (2007).

26.

Violin, J. D. & Lefkowitz, R. J. β-Arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci. 28, 416–422 (2007).

27.

Spengler, D. et al. Differential signal transduction by five splice variants of the PACAP receptor. Nature 365, 170–175 (1993).

28.

Kenakin, T. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci. 16, 232–238 (1995).

29.

Gurwitz, D. et al. Discrete activation of transduction pathways associated with acetylcholine m1 receptor by several muscarinic ligands. Eur. J. Pharmacol. 267, 21–31 (1994).

30.

Wei, H. et al. Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc. Natl Acad. Sci. USA 100, 10782–10787 (2003).

31.

Whalen, E. J., Rajagopal, S. & Lefkowitz, R. J. Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol. Med. 17, 126–139 (2011).

32.

Violin, J. D., Crombie, A. L., Soergel, D. G. & Lark, M. W. Biased ligands at G-protein-coupled receptors: promise and progress. Trends Pharmacol Sci. 35, 308–316 (2014).

33.

Wisler, J. W., Xiao, K., Thomsen, A. R. & Lefkowitz, R. J. Recent developments in biased agonism. Curr. Opin. Cell Biol. 27, 18–24 (2014).

34.

Rajagopal, S., Rajagopal, K. & Lefkowitz, R. J. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. 9, 373–386 (2010).

35.

Samama, P., Cotecchia, S., Costa, T. & Lefkowitz, R. J. A mutation-induced activated state of the β2-adrenergic receptor. Extending the ternary complex model. J. Biol Chem. 268, 4625–4636 (1993).

36.

Changeux, J. P. & Edelstein, S. J. Allosteric mechanisms of signal transduction. Science 308, 1424–1428 (2005).

37.

Kenakin, T. P. Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Br. J. Pharmacol. 165, 1659–1669 (2012).

38.

De Lean, A., Stadel, J. M. & Lefkowitz, R. J. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J. Biol Chem. 255, 7108–7117 (1980).

39.

Gentry, P. R., Sexton, P. M. & Christopoulos, A. Novel allosteric modulators of G protein-coupled receptors. J. Biol Chem. 290, 19478–19488 (2015).

40.

Onaran, H. O., Rajagopal, S. & Costa, T. What is biased efficacy? Defining the relationship between intrinsic efficacy and free energy coupling. Trends Pharmacol Sci. 35, 639–647 (2014).

41.

Kenakin, T. Gaddum Memorial Lecture 2014: receptors as an evolving concept: from switches to biased microprocessors. Br. J. Pharmacol. 172, 4238–4253 (2015).

42.

Galandrin, S., Oligny-Longpre, G. & Bouvier, M. The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci. 28, 423–430 (2007).

43.

Wardell, S. E., Marks, J. R. & McDonnell, D. P. The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. Biochem. Pharmacol. 82, 122–130 (2011).

44.

Norris, J. D. et al. Peptide antagonists of the human estrogen receptor. Science 285, 744–746 (1999).

45.

Paige, L. A. et al. Estrogen receptor (ER) modulators each induce distinct conformational changes in ERα and ERβ. Proc. Natl Acad. Sci. USA 96, 3999–4004 (1999).

46.

Heldring, N. et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev. 87, 905–931 (2007).

47.

Kovalenko, M. et al. Phosphorylation site-specific inhibition of platelet-derived growth factor β-receptor autophosphorylation by the receptor blocking tyrphostin AG1296. Biochemistry 36, 6260–6269 (1997).

48.

Girnita, L. et al. β-Arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression. J. Biol Chem. 282, 11329–11338 (2007).

49.

Arey, B. J. et al. Induction of promiscuous G protein coupling of the follicle-stimulating hormone (FSH) receptor: a novel mechanism for transducing pleiotropic actions of FSH isoforms. Mol. Endocrinol. 11, 517–526 (1997).

50.

Arey, B. J. et al. Differing pharmacological activities of thiazolidinone analogs at the FSH receptor. Biochem. Biophys. Res. Commun. 368, 723–728 (2008).

51.

Yanofsky, S. D. et al. Allosteric activation of the follicle-stimulating hormone (FSH) receptor by selective, nonpeptide agonists. J. Biol Chem. 281, 13226–13233 (2006).

52.

Kjelsberg, M. A., Cotecchia, S., Ostrowski, J., Caron, M. G. & Lefkowitz, R. J. Constitutive activation of the α1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. J. Biol Chem. 267, 1430–1433 (1992).

53.

Chen, X., Bai, B., Tian, Y., Du, H. & Chen, J. Identification of serine 348 on the apelin receptor as a novel regulatory phosphorylation site in apelin-13-induced G protein-independent biased signaling. J. Biol Chem. 289, 31173–31187 (2014).

54.

Wanka, L. et al. C-Terminal motif of human neuropeptide Y4 receptor determines internalization and arrestin recruitment. Cell. Signal. 29, 233–239 (2017).

55.

Rajagopal, S. et al. β-Arrestin-but not G protein-mediated signaling by the “decoy” receptor CXCR7. Proc. Natl Acad. Sci. USA 107, 628–632 (2010).

56.

Levoye, A., Balabanian, K., Baleux, F., Bachelerie, F. & Lagane, B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 113, 6085–6093 (2009).

57.

Decaillot, F. M. et al. CXCR7/CXCR4 heterodimer constitutively recruits β-arrestin to enhance cell migration. J. Biol Chem. 286, 32188–32197 (2011).

58.

Wang, Y. et al. CXCR4 and CXCR7 have distinct functions in regulating interneuron migration. Neuron 69, 61–76 (2011).

59.

Smith, J. S. et al. C-X-C motif chemokine receptor 3 splice variants differentially activate beta-arrestins to regulate downstream signaling pathways. Mol. Pharmacol. 92, 136–150 (2017).

60.

Berchiche, Y. A. & Sakmar, T. P. CXC chemokine receptor 3 alternative splice variants selectively activate different signaling pathways. Mol. Pharmacol. 90, 483–495 (2016).

61.

Armbruster, B. N., Li, X., Pausch, M. H., Herlitze, S. & Roth, B. L. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc. Natl Acad. Sci. USA 104, 5163–5168 (2007).

62.

Nakajima, K. & Wess, J. Design and functional characterization of a novel, arrestin-biased designer G protein-coupled receptor. Mol. Pharmacol. 82, 575–582 (2012).

63.

Hu, J. et al. A G protein-biased designer G protein-coupled receptor useful for studying the physiological relevance of Gq/11-dependent signaling pathways. J. Biol Chem. 291, 7809–7820 (2016).

64.

Siuda, E. R. et al. Optodynamic simulation of beta-adrenergic receptor signalling. Nat. Commun. 6, 8480 (2015).

65.

Spangler, S. M. & Bruchas, M. R. Optogenetic approaches for dissecting neuromodulation and GPCR signaling in neural circuits. Curr. Opin. Pharmacol. 32, 56–70 (2017).

66.

Reiter, E. & Lefkowitz, R. J. GRKs and β-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol. Metab. 17, 159–165 (2006).

67.

Zidar, D. A., Violin, J. D., Whalen, E. J. & Lefkowitz, R. J. Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc. Natl Acad. Sci. USA 106, 9649–9654 (2009).

68.

Riggs, B. L. & Hartmann, L. C. Selective estrogen-receptor modulators — mechanisms of action and application to clinical practice. N. Engl. J. Med. 348, 618–629 (2003).

69.

Urs, N. M. et al. Distinct cortical and striatal actions of a β-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties. Proc. Natl Acad. Sci. USA 113, E8178–E8186 (2016). This paper presents a physiological example of how system bias can influence β-arrestin signalling.

70.

Schattauer, S. S., Kuhar, J. R., Song, A. & Chavkin, C. Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor. Cell. Signal. 32, 59–65 (2017).

71.

Shenoy, S. K. & Lefkowitz, R. J. β-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci. 32, 521–533 (2011).

72.

Kim, J. et al. Functional antagonism of different G protein-coupled receptor kinases for β-arrestin-mediated angiotensin II receptor signaling. Proc. Natl Acad. Sci. USA 102, 1442–1447 (2005).

73.

Busillo, J. M. et al. Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. J. Biol Chem. 285, 7805–7817 (2010).

74.

Nobles, K. N. et al. Distinct phosphorylation sites on the β2-adrenergic receptor establish a barcode that encodes differential functions of β-arrestin. Sci. Signal. 4, ra51 (2011).

75.

Butcher, A. J. et al. Differential G-protein-coupled receptor phosphorylation provides evidence for a signaling bar code. J. Biol Chem. 286, 11506–11518 (2011). References 72–75 are some of the key papers demonstrating 'barcode' patterns, indicating how site-specific phosphorylation regulates GPCR signalling.

76.

Poulin, B. et al. The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner. Proc. Natl Acad. Sci. USA 107, 9440–9445 (2010).

77.

Luo, J., Busillo, J. M., Stumm, R. & Benovic, J. L. G. Protein-coupled receptor kinase 3 and protein kinase C phosphorylate the distal C-terminal tail of the chemokine receptor CXCR4 and mediate recruitment of β-arrestin. Mol. Pharmacol. 91, 554–566 (2017).

78.

Shukla, A. K. et al. Distinct conformational changes in β-arrestin report biased agonism at seven-transmembrane receptors. Proc. Natl Acad. Sci. USA 105, 9988–9993 (2008).

79.

Charest, P. G., Terrillon, S. & Bouvier, M. Monitoring agonist-promoted conformational changes of β-arrestin in living cells by intramolecular BRET. EMBO Rep. 6, 334–340 (2005).

80.

Namkung, Y. et al. Monitoring G protein-coupled receptor and β-arrestin trafficking in live cells using enhanced bystander BRET. Nat. Commun. 7, 12178 (2016).

81.

Lee, M. H. et al. The conformational signature of β-arrestin2 predicts its trafficking and signalling functions. Nature 531, 665–668 (2016).

82.

Nuber, S. et al. β-Arrestin biosensors reveal a rapid, receptor-dependent activation/deactivation cycle. Nature 531, 661–664 (2016). References 81 and 82 are studies that link β-arrestin conformation with function.

83.

Hernandez, P. A. et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat. Genet. 34, 70–74 (2003).

84.

Balabanian, K. et al. WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood 105, 2449–2457 (2005).

85.

Barak, L. S., Oakley, R. H., Laporte, S. A. & Caron, M. G. Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. Proc. Natl Acad. Sci. USA 98, 93–98 (2001).

86.

Wootten, D. et al. The extracellular surface of the GLP-1 receptor is a molecular trigger for biased agonism. Cell 165, 1632–1643 (2016). This paper presents important mechanistic work on how receptor mutants can bias signalling responses.

87.

Wootten, D. et al. Key interactions by conserved polar amino acids located at the transmembrane helical boundaries in Class B GPCRs modulate activation, effector specificity and biased signalling in the glucagon-like peptide-1 receptor. Biochem. Pharmacol. 118, 68–87 (2016).

88.

Wootten, D. et al. A hydrogen-bonded polar network in the core of the glucagon-like peptide-1 receptor is a fulcrum for biased agonism: lessons from class B crystal structures. Mol. Pharmacol. 89, 335–347 (2016).

89.

Cherezov, V. et al. High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor. Science 318, 1258��1265 (2007).

90.

Venkatakrishnan, A. J. et al. Diverse activation pathways in class A GPCRs converge near the G-protein-coupling region. Nature 536, 484–487 (2016).

91.

Katritch, V., Cherezov, V. & Stevens, R. C. Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol Sci. 33, 17–27 (2012).

92.

Zhang, H. et al. Structure of the Angiotensin receptor revealed by serial femtosecond crystallography. Cell 161, 833–844 (2015).

93.

Zhang, H. et al. Structural basis for ligand recognition and functional selectivity at angiotensin receptor. J. Biol Chem. 290, 29127–29139 (2015).

94.

Choe, H. W. et al. Crystal structure of metarhodopsin II. Nature 471, 651–655 (2011).

95.

Standfuss, J. et al. The structural basis of agonist-induced activation in constitutively active rhodopsin. Nature 471, 656–660 (2011).

96.

Lebon, G. et al. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 474, 521–525 (2011).

97.

Jaakola, V. P. et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322, 1211–1217 (2008).

98.

Xu, F. et al. Structure of an agonist-bound human A2A adenosine receptor. Science 332, 322–327 (2011).

99.

Kruse, A. C. et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504, 101–106 (2013).

100.

Manglik, A. et al. Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. Nature 485, 321–326 (2012).

101.

Huang, W. et al. Structural insights into micro-opioid receptor activation. Nature 524, 315–321 (2015).

102.

Zheng, Y. et al. Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists. Nature 540, 458–461 (2016).

103.

Oswald, C. et al. Intracellular allosteric antagonism of the CCR9 receptor. Nature 540, 462–465 (2016).

104.

Hollenstein, K. et al. Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 499, 438–443 (2013).

105.

Jazayeri, A. et al. Extra-helical binding site of a glucagon receptor antagonist. Nature 533, 274–277 (2016).

106.

Rasmussen, S. G. et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 477, 549–555 (2011).

107.

Liang, Y. L. et al. Phase-plate cryo-EM structure of a class B GPCR-G-protein complex. Nature 546, 118–123 (2017).

108.

Zhang, Y. et al. Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein. Nature 546, 248–253 (2017). References 107 and 108 are structural studies utilizing cryo-EM to solve GPCR structures in complex with G proteins. Cryo-EM technology will likely play an important role in providing critical structural insights into biased signalling.

109.

Zhang, H. et al. Structural basis for selectivity and diversity in angiotensin II receptors. Nature 544, 327–332 (2017).

110.

Burg, J. S. et al. Structural basis for chemokine recognition and activation of a viral G protein-coupled receptor. Science 347, 1113–1117 (2015).

111.

Carpenter, B., Nehme, R., Warne, T., Leslie, A. G. & Tate, C. G. Structure of the adenosine A2A receptor bound to an engineered G protein. Nature 536, 104–107 (2016).

112.

Staus, D. P. et al. Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation. Nature 535, 448–452 (2016).

113.

Kim, Y. J. et al. Crystal structure of pre-activated arrestin p44. Nature 497, 142–146 (2013).

114.

Kang, Y. et al. Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser. Nature 523, 561–567 (2015).

115.

Szczepek, M. et al. Crystal structure of a common GPCR-binding interface for G protein and arrestin. Nat. Commun. 5, 4801 (2014).

116.

Renaud, J. P. et al. Biophysics in drug discovery: impact, challenges and opportunities. Nat. Rev. Drug Discov. 15, 679–698 (2016).

117.

Westfield, G. H. et al. Structural flexibility of the Gαs α-helical domain in the β2-adrenoceptor Gs complex. Proc. Natl Acad. Sci. USA 108, 16086–16091 (2011).

118.

Shukla, A. K. et al. Visualization of arrestin recruitment by a G-protein-coupled receptor. Nature 512, 218–222 (2014).

119.

Kumari, P. et al. Functional competence of a partially engaged GPCR-β-arrestin complex. Nat. Commun. 7, 13416 (2016).

120.

Cahill, T. J. et al. Distinct conformations of GPCR-β-arrestin complexes mediate desensitization, signaling, and endocytosis. Proc. Natl Acad. Sci. USA 114, 2562–2567 (2017).

121.

Thomsen, A. R. et al. GPCR-G protein-β-arrestin super-complex mediates sustained G protein signaling. Cell 166, 907–919 (2016). This is a negative stain EM study that provides a potential structural basis for how β-arrestin and G proteins can orchestrate prolonged intracellular GPCR signalling.

122.

Kahsai, A. W. et al. Multiple ligand-specific conformations of the β2-adrenergic receptor. Nat. Chem. Biol. 7, 692–700 (2011).

123.

Isogai, S. et al. Backbone NMR reveals allosteric signal transduction networks in the β1-adrenergic receptor. Nature 530, 237–241 (2016).

124.

Perez-Aguilar, J. M., Shan, J., LeVine, M. V., Khelashvili, G. & Weinstein, H. A functional selectivity mechanism at the serotonin-2A GPCR involves ligand-dependent conformations of intracellular loop 2. J. Am. Chem. Soc. 136, 16044–16054 (2014).

125.

Kim, I. M. et al. β-Blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivation. Proc. Natl Acad. Sci. USA 105, 14555–14560 (2008).

126.

Kim, I. M. et al. β-Arrestin1-biased β1-adrenergic receptor signaling regulates microRNA processing. Circ. Res. 114, 833–844 (2014).

127.

Wisler, J. W. et al. A unique mechanism of β-blocker action: carvedilol stimulates β-arrestin signaling. Proc. Natl Acad. Sci. USA 104, 16657–16662 (2007).

128.

Liu, J. J., Horst, R., Katritch, V., Stevens, R. C. & Wuthrich, K. Biased signaling pathways in β2-adrenergic receptor characterized by 19F-NMR. Science 335, 1106–1110 (2012).

129.

Kahsai, A. W. et al. Conformationally selective RNA aptamers allosterically modulate the β2-adrenoceptor. Nat. Chem. Biol. 12, 709–716 (2016).

130.

Nygaard, R. et al. The dynamic process of β2-adrenergic receptor activation. Cell 152, 532–542 (2013).

131.

Manglik, A. et al. Structural insights into the dynamic process of β2-adrenergic receptor signaling. Cell 161, 1101–1111 (2015).

132.

Mary, S. et al. Ligands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor. Proc. Natl Acad. Sci. USA 109, 8304–8309 (2012).

133.

Wacker, D. et al. Structural features for functional selectivity at serotonin receptors. Science 340, 615–619 (2013).

134.

Yang, F. et al. Phospho-selective mechanisms of arrestin conformations and functions revealed by unnatural amino acid incorporation and 19F-NMR. Nat. Commun. 6, 8202 (2015).

135.

Ariens, E. J. Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory. Arch. Intern. Pharmacodynamie Therapie 99, 32–49 (1954).

136.

Stephenson, R. P. A modification of receptor theory. Br. J. Pharmacol. Chemother. 11, 379–393 (1956).

137.

Furchgott, R. F. in in Advances in Drug Research Vol. 3 (eds Harper, N. J. & Simmonds, A. B.) 21–55 (Academic Press, 1966).

138.

Black, J. W. & Leff, P. Operational models of pharmacological agonism. Proc. R. Soc. Lond. B Biol Sci. 220, 141–162 (1983).

139.

Rajagopal, S. et al. Quantifying ligand bias at seven-transmembrane receptors. Mol. Pharmacol. 80, 367–377 (2011).

140.

Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A. & Novick, S. A simple method for quantifying functional selectivity and agonist bias. ACS Chem. Neurosci. 3, 193–203 (2012).

141.

Griffin, M. T., Figueroa, K. W., Liller, S. & Ehlert, F. J. Estimation of agonist activity at G protein-coupled receptors: analysis of M2 muscarinic receptor signaling through Gi/o, Gs, and G15. J. Pharmacol. Exp. Ther. 321, 1193–1207 (2007).

142.

Snyder, J. C., Rochelle, L. K., Lyerly, H. K., Caron, M. G. & Barak, L. S. Constitutive internalization of the leucine-rich G protein-coupled receptor-5 (LGR5) to the trans-Golgi network. J. Biol Chem. 288, 10286–10297 (2013).

143.

Onaran, H. O. et al. Systematic errors in detecting biased agonism: analysis of current methods and development of a new model-free approach. Sci. Rep. 7, 44247 (2017). This is a detailed comparison of different methods to quantify biased signalling.

144.

Gregory, K. J., Hall, N. E., Tobin, A. B., Sexton, P. M. & Christopoulos, A. Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. J. Biol Chem. 285, 7459–7474 (2010).

145.

Strachan, R. T. et al. Divergent transducer-specific molecular efficacies generate biased agonism at a G protein-coupled receptor (GPCR). J. Biol. Chem. 289, 14211–14224 (2014).

146.

Moffat, J. G., Vincent, F., Lee, J. A., Eder, J. & Prunotto, M. Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nat. Rev. Drug Discov. 16, 531–543 (2017).

147.

Jones, L. H. & Bunnage, M. E. Applications of chemogenomic library screening in drug discovery. Nat. Rev. Drug Discov. 16, 285–296 (2017).

148.

Horvath, P. et al. Screening out irrelevant cell-based models of disease. Nat. Rev. Drug Discov. 15, 751–769 (2016).

149.

Swinney, D. C. & Anthony, J. How were new medicines discovered? Nat. Rev. Drug Discov. 10, 507–519 (2011).

150.

Whistler, J. L., Chuang, H. H., Chu, P., Jan, L. Y. & von Zastrow, M. Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 23, 737–746 (1999).

151.

Zhang, J. et al. Role for G protein-coupled receptor kinase in agonist-specific regulation of μ-opioid receptor responsiveness. Proc. Natl Acad. Sci. USA 95, 7157–7162 (1998).

152.

Melief, E. J., Miyatake, M., Bruchas, M. R. & Chavkin, C. Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. Proc. Natl Acad. Sci. USA 107, 11608–11613 (2010).

153.

Bohn, L. M., Gainetdinov, R. R., Lin, F. T., Lefkowitz, R. J. & Caron, M. G. μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence. Nature 408, 720–723 (2000).

154.

Bohn, L. M. et al. Enhanced morphine analgesia in mice lacking β-arrestin 2. Science 286, 2495–2498 (1999).

155.

Groer, C. E. et al. An opioid agonist that does not induce μ-opioid receptor-arrestin interactions or receptor internalization. Mol. Pharmacol. 71, 549–557 (2007).

156.

Soergel, D. G. et al. Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain 155, 1829–1835 (2014).

157.

Viscusi, E. R. et al. A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain. Pain 157, 264–272 (2016).

158.

Manglik, A. et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature 537, 185–190 (2016). This is a manuscript describing the design of a biased agonist, from a structure-based approach to physiological effects.

159.

Land, B. B. et al. The dysphoric component of stress is encoded by activation of the dynorphin κ-opioid system. J. Neurosci. 28, 407–414 (2008).

160.

White, K. L. & Roth, B. L. Psychotomimetic effects of kappa opioid receptor agonists. Biol Psychiatry 72, 797–798 (2012).

161.

Bruchas, M. R. et al. Selective p38α MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction. Neuron 71, 498–511 (2011).

162.

Land, B. B. et al. Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking. Proc. Natl Acad. Sci. USA 106, 19168–19173 (2009).

163.

Ehrich, J. M. et al. Kappa opioid receptor-induced aversion requires p38 MAPK activation in VTA dopamine neurons. J. Neurosci. 35, 12917–12931 (2015).

164.

Brust, T. F. et al. Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria. Sci. Signal. 9, ra117 (2016).

165.

White, K. L. et al. The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo. J. Pharmacol. Exp. Ther. 352, 98–109 (2015).

166.

Maillet, E. L. et al. Noribogaine is a G-protein biased κ-opioid receptor agonist. Neuropharmacology 99, 675–688 (2015).

167.

White, K. L. et al. Identification of novel functionally selective κ-opioid receptor scaffolds. Mol. Pharmacol. 85, 83–90 (2014).

168.

Rives, M. L., Rossillo, M., Liu-Chen, L. Y. & Javitch, J. A. 6′-Guanidinonaltrindole (6′-GNTI) is a G protein-biased κ-opioid receptor agonist that inhibits arrestin recruitment. J. Biol Chem. 287, 27050–27054 (2012).

169.

Lovell, K. M. et al. Structure-activity relationship studies of functionally selective kappa opioid receptor agonists that modulate ERK 1/2 phosphorylation while preserving G protein over βarrestin2 signaling bias. ACS Chem. Neurosci. 6, 1411–1419 (2015).

170.

Zhou, L. et al. Development of functionally selective, small molecule agonists at kappa opioid receptors. J. Biol Chem. 288, 36703–36716 (2013).

171.

Melief, E. J. et al. Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation. Mol. Pharmacol. 80, 920–929 (2011).

172.

Munro, T. A. et al. Long-acting kappa opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity. BMC Pharmacol. 12, 5 (2012).

173.

Carroll, F. I. & Carlezon, W. A. Jr. Development of kappa opioid receptor antagonists. J. Med. Chem. 56, 2178–2195 (2013).

174.

Chavkin, C. & Koob, G. F. Dynorphin, dysphoria, and dependence: the stress of addiction. Neuropsychopharmacology 41, 373–374 (2016).

175.

Van't Veer, A. & Carlezon, W. A. Jr. Role of κ-opioid receptors in stress and anxiety-related behavior. Psychopharmacology 229, 435–452 (2013).

176.

Howes, O. D. & Kapur, S. The dopamine hypothesis of schizophrenia: version III — the final common pathway. Schizophr. Bull. 35, 549–562 (2009).

177.

Free, R. B. et al. Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptor. Mol. Pharmacol. 86, 96–105 (2014).

178.

Shonberg, J. et al. A structure-activity analysis of biased agonism at the dopamine D2 receptor. J. Med. Chem. 56, 9199–9221 (2013).

179.

Chen, X. et al. Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D2 receptor agonists. J. Med. Chem. 55, 7141–7153 (2012).

180.

Allen, J. A. et al. Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc. Natl Acad. Sci. USA 108, 18488–18493 (2011).

181.

Park, S. M. et al. Effects of β-arrestin-biased dopamine D2 receptor ligands on schizophrenia-like behavior in hypoglutamatergic mice. Neuropsychopharmacology 41, 704–715 (2016).

182.

Urs, N. M., Peterson, S. M. & Caron, M. G. New concepts in dopamine D2 receptor biased signaling and implications for schizophrenia therapy. Biol Psychiatry 81, 78–85 (2016).

183.

Sexton, P. M., Findlay, D. M. & Martin, T. J. Calcitonin. Curr. Med. Chem. 6, 1067–1093 (1999).

184.

Andreassen, K. V. et al. Prolonged calcitonin receptor signaling by salmon, but not human calcitonin, reveals ligand bias. PLoS ONE 9, e92042 (2014).

185.

Furness, S. G. et al. Ligand-dependent modulation of G protein conformation alters drug efficacy. Cell 167, 739–749.e11 (2016).

186.

Bachelerie, F. et al. International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 66, 1–79 (2014).

187.

Steen, A., Larsen, O., Thiele, S. & Rosenkilde, M. M. Biased and G protein-independent signaling of chemokine receptors. Front. Immunol. 5, 277 (2014).

188.

Muller, M., Carter, S., Hofer, M. J. & Campbell, I. L. Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity — a tale of conflict and conundrum. Neuropathol. Appl. Neurobiol. 36, 368–387 (2010).

189.

Groom, J. R. & Luster, A. D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol. 89, 207–215 (2011).

190.

Rashighi, M. et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci. Transl Med. 6, 223ra23 (2014).

191.

Rajagopal, S. et al. Biased agonism as a mechanism for differential signaling by chemokine receptors. J. Biol Chem. 288, 35039–35048 (2013).

192.

Zohar, Y. et al. CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis. J. Clin. Invest. 124, 2009–2022 (2014).

193.

Kohout, T. A. et al. Differential desensitization, receptor phosphorylation, β-arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7. J. Biol Chem. 279, 23214–23222 (2004).

194.

Drury, L. J. et al. Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways. Proc. Natl Acad. Sci. USA 108, 17655–17660 (2011).

195.

Corbisier, J., Gales, C., Huszagh, A., Parmentier, M. & Springael, J. Y. Biased signaling at chemokine receptors. J. Biol Chem. 290, 9542–9554 (2015).

196.

Corbisier, J., Huszagh, A., Gales, C., Parmentier, M. & Springael, J. Y. Partial agonist and biased signaling properties of the synthetic enantiomers J113863/UCB35625 at chemokine receptors CCR2 and CCR5. J. Biol Chem. 292, 575–584 (2016).

197.

Felker, G. M. et al. Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). JACC Heart Fail. 3, 193–201 (2015).

198.

Abraham, D. M. et al. β-Arrestin mediates the Frank-Starling mechanism of cardiac contractility. Proc. Natl Acad. Sci. USA 113, 14426–14431 (2016).

199.

Liu, C. H. et al. Arrestin-biased AT1R agonism induces acute catecholamine secretion through TRPC3 coupling. Nat. Commun. 8, 14335 (2017).

200.

Donato, M. & Gelpi, R. J. Adenosine and cardioprotection during reperfusion — an overview. Mol. Cell. Biochem. 251, 153–159 (2003).

201.

Welihinda, A. A., Kaur, M., Greene, K., Zhai, Y. & Amento, E. P. The adenosine metabolite inosine is a functional agonist of the adenosine A2A receptor with a unique signaling bias. Cell. Signal. 28, 552–560 (2016).

202.

Vecchio, E. A. et al. The hybrid molecule, VCP746, is a potent adenosine A2B receptor agonist that stimulates anti-fibrotic signalling. Biochem. Pharmacol. 117, 46–56 (2016).

203.

Aurelio, L. et al. Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. J. Med. Chem. 52, 4543–4547 (2009).

204.

Valant, C. et al. Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Proc. Natl Acad. Sci. USA 111, 4614–4619 (2014).

205.

Chuo, C. H. et al. VCP746, a novel A1 adenosine receptor biased agonist, reduces hypertrophy in a rat neonatal cardiac myocyte model. Clin. Exp. Pharmacol. Physiol. 43, 976–982 (2016).

206.

Baltos, J. A. et al. Structure-activity analysis of biased agonism at the human adenosine A3 receptor. Mol. Pharmacol. 90, 12–22 (2016).

207.

Barak, L. S. et al. ML314: a biased neurotensin receptor ligand for methamphetamine abuse. ACS Chem. Biol. 11, 1880–1890 (2016).

208.

Peddibhotla, S. et al. Discovery of ML314, a brain penetrant non-peptidic β-arrestin biased agonist of the neurotensin NTR1 receptor. ACS Med. Chem. Lett. 4, 846–851 (2013).

209.

Quoyer, J. et al. Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein. Proc. Natl Acad. Sci. USA 110, E5088–E5097 (2013).

210.

Wacker, D. et al. Crystal structure of an LSD-bound human serotonin receptor. Cell 168, 377–389.e12 (2017).

211.

Mallipeddi, S., Janero, D. R., Zvonok, N. & Makriyannis, A. Functional selectivity at G-protein coupled receptors: advancing cannabinoid receptors as drug targets. Biochem. Pharmacol. 128, 1–11 (2016).

212.

Ahn, K. H., Mahmoud, M. M., Shim, J. Y. & Kendall, D. A. Distinct roles of β-arrestin 1 and β-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1). J. Biol Chem. 288, 9790–9800 (2013).

213.

Fay, J. F. & Farrens, D. L. Structural dynamics and energetics underlying allosteric inactivation of the cannabinoid receptor CB1. Proc. Natl Acad. Sci. USA 112, 8469–8474 (2015).

214.

Mancini, A. D. et al. β-Arrestin recruitment and biased agonism at free fatty acid receptor 1. J. Biol Chem. 290, 21131–21140 (2015).

215.

Christopoulos, A. Advances in G protein-coupled receptor allostery: from function to structure. Mol. Pharmacol. 86, 463–478 (2014).

216.

Kenakin, T. & Christopoulos, A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat. Rev. Drug Discov. 12, 205–216 (2013).

217.

Rajagopal, S. Quantifying biased agonism: understanding the links between affinity and efficacy. Nat. Rev. Drug Discov. 12, 483 (2013).

218.

Kenakin, T. & Christopoulos, A. Measurements of ligand bias and functional affinity. Nat. Rev. Drug Discov. 12, 483 (2013).

219.

Breton, B. et al. Multiplexing of multicolor bioluminescence resonance energy transfer. Biophys. J. 99, 4037–4046 (2010).

220.

Kroeze, W. K. et al. PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome. Nat. Struct. Mol. Biol. 22, 362–369 (2015).

221.

Devost, D. et al. Conformational profiling of the AT1 angiotensin II receptor reflects biased agonism, G protein coupling, and cellular context. J. Biol Chem. 292, 5443–5456 (2017).

222.

Barak, L. S., Ferguson, S. S., Zhang, J. & Caron, M. G. A β-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J. Biol Chem. 272, 27497–27500 (1997).

223.

Inoue, A. et al. TGFα shedding assay: an accurate and versatile method for detecting GPCR activation. Nat. Methods 9, 1021–1029 (2012).

— Nature Reviews Drug Discovery

[marigabicb]

De vuelta de la locura de Paris Photo, os cuento aquí mi experiencia de una semana larga y tan corta a la vez, pasada corriendo cerca del Sena… Esto es solo un relato, cada cual que ha estado en París tendrá el suyo.

Un año mas, y se repiten las palabras del año pasado por las mismas fechas: las ganas de encontrarse con caras conocidas, la intención de comprar menos libros, de evitar la ansiedad, de disfrutar de Paris y sus exposiciones. Pasa el tiempo y la ciudad sigue siendo tan atractiva, un nudo emocional, gigantesco “hub” para los amantes de la fotografía y los fotolibros. Para mi, lejos de Hondarribia, es una vez más la oportunidad de ver a los amigos, de echar de menos a otros que no han podido venir, de conocer caras nuevas, de hablar de la colección en San Telmo y los nuevos proyectos.

    París es mucho París, y la oferta cultural es inabarcable, además de la propia feria. La lista de exposiciones imprescindibles ya daba vértigo antes de llegar. Sophie Calle, Penn, Sibidé, Dragana Jurisic, Albert Renger-Patzsch, El MoMa en la Fundación Vuitton, Dada Africa, Clément Cogitore en Le Bal, el Palais de Tokyo, Paysages Français en la Bibliothèque Nationale  etc, etc…sabía que iba a sufrir por no poder ver todo. Y así fue.

Sin contar los innumerables eventos organizados alrededor de la feria, como Photo Saint-Germain, o los pop-up de galerías o editores… En cuanto a la feria, este año ( un año mas…) iba con el firme propósito de no caer en la tentación pletórica de Offprint, y casi casi lo consigo…

Polycopies no se puede evitar, para que ir a París si no ?… Desde hace 3 ( o son 4 ya? ) años, el barco Concorde-Atlantique es el mejor sitio de la ciudad para ver y hablar de fotolibros, y encontrarse con conocidos y amigos, muchos, con o sin libro nuevo.

Empecé el maratón parisino en el siempre interesante Palais de Tokyo, muy cerca de donde estaba hospedada, viendo una exposición de la francesa Camille Henrot, videos o instalaciones, a punto de caer en su río de oro. La visita ha resultado menos intensa que la del año pasado, pero este otro Palais siempre vale la pena ( y su librería ! )

  Visité el día de la inauguración los pasillos alfombrados del Grand Palais, como visitas un museo, entre admiración, deseo y frustración, pero también con estoicismo, entre tesoros vintage y simpáticos VIPs ( Patti Smith comisariaba un espacio, con buenas fotografías ). Obras de Jungjin Lee ( fabulosa ), Hosoe, Masao Yamamoto, Miho Kajioka ( con el enorme placer de saludarle a los pocos días! ), un precioso Adam Fuss en la galería Fraenkel, la estupenda presentación de Astres Noirs en la East Gallery, impecable Dieter Appelt en Galerie Françoise Paviot, Nathalie Boutté en Yossi Milo y Magnin, el Trump l’oeil de Mishka Henner… Espectadora afortunada, aunque no lo suficiente para adquirir las obras, pero saber que están ahí me basta. Y añado que hacer la visita con mi amigo Patrick Maille, saludar a Kazuma Obara o a Vita y Boris Mikhailov es una gran alegría.

Pasé mas tiempo esta vez viendo galerías que editores, por no caer en la tentación, (que me pareció algo menor este año),  aunque ver la lista de nominados al premio Aperture es obligado, y agotador por la presencia masiva de gente. Tres filas para acceder a Steidl, o la cola días más tarde para la firma de Alec Soth en Mack es señal de buena salud para esas editoriales o la afición al fotolibro, menos para mi, ya mareada a esa hora…

Luego la primera de muchas visitas al barco de Polycopies, para saludar, y vuelta a casa.

    Jueves. La exposición de Albert Renger-Patzsch en Jeu de Paume ya estuvo en Madrid, pero no tuve ocasión de verla allí. Magnificas y sobrecogedoras sus fotografías de  bosques o paisajes. Renger-Patzsch ya había inventado muchas cosas que se han visto mucho más tarde.

  Y de ahí otra vez al barco, donde vi a más amigos, entre ellos Christer Ek, o Juan Cires, y como ya es habitual, mucha presencia española. En la mesa de Dalpine, Sonia había recibido ya A Google Life, de Olga Bushkova, libro ganador del premio a mejor maqueta en Fiebre Photobooks. Montse Puig e Israel Ariño, (el con una bella exposición en el Grand Palais de la mano de Galerie Vu ), los Anómalas, ya tenían desplegados sus libros, los japoneses de Zen Photo atraían a cualquiera con sus joyas exóticas… El Tipi de Andrea Copetti ya rebosaba de ediciones independientes, y en el piso de abajo, mas exotismo con libros rusos, turcos o rumanos, entre otros,  de lo mas apetecibles. Caes en la tentación…

    Esa tarde se abría Offprint, pero yo me fui a la inauguración de la exposición My own unknown, de Dragana Jurisic, en el Institut Culturel Irlandais, con presentación de la gran artista con Natasha Christia. Una bella exposición de la fotógrafa “ex Yugoslava” afincada en Irlanda, todo un lujo que te permite París esos días.

      Y otro visita también a la exposición “Jeune”, en el Crous de la rue des Beaux Arts, dentro del marco de Photo Saint-Germain, otro evento en el famoso barrio “Rive Gauche”, con muchas exposiciones programadas. Allí exponían Bérangère Fromont y Joseph Charroy, entre otros. Como también lo hacía Léa Habourdin en el espacio mágico de Deyrolle, en rue du Bac, con Everything becomes nothing again. Correr y correr para no perderse nada, así es la vida del “foto drug addict” en París.

    Dormir, y recuperar fuerzas…

Viernes. Visita a la fabulosa exposición de Sophie Calle, y su invitada Serena Carone en el no menos fabuloso Musée de la Chasse et la nature, en rue des Archives. Beau doublé, Monsieur le Marquis , comisariada por Sonia Voss, es un recorrido entre bestiario y autobiografía, y mucho más.

    Me gusta mucho el trabajo de Sophie Calle, su vida ofrecida con humor y poco pudor, pero con una gran delicadeza y sensibilidad. Maravilla de equilibrio entre el drama y la ligereza, entre lo absurdo, lo crudo, lo tierno y lo tan real. Sus obras instaladas en los salones del “Hotel Guénégaud” del siglo XVIII, construido por Mansart, entre marcos dorados, muebles antiguos y sala de armería, es una experiencia irrepetible que solo os puedo recomendar si pasáis por París antes de que acabe la exposición, el 18 de febrero 2018. He tenido además la suerte de visitar la exposición con mi amiga Annakarin Quinto, y de encontrarme allí con Magali Avezou, de archipelago projects ( que luego no vería en Offprint, desgraciadamente ) y Amak Mahmoodian. Un muy gran recuerdo.

Por la tarde por fin llegué a Offprint, en la rue Bonaparte. Fue una visita demasiado corta, en parte para evitar tentaciones, y porque quería seguir más tarde el maratón. Allí unos cuantas paradas para ver a Tiane Doan na Champassak y sus ultimos libros, a Maya Rochat ahora en Self Publish Be Happy, a Kominek con la muy esperada publicación de Bryan Schutmaat, al adorado Stephen Gill. Sergej Vutuc, Patrick Frey, vistazo a Spector books, y ponerse los antifaces para no ver mas.

  Desde ahí vuelta al Marais, donde Steve Bisson presentaba las novedades de Urbanautica, con el libro de Andrés Medina entre ellos. Bisson es un hombre de mucho gusto, y sus ediciones nuevas son libros sencillos de aspecto pero interesantes y con un acabado de mucha calidad y delicadeza. Andrés no ha podido estar en París, pero Río estaba en buen sitio.

    Cerca de allí se encontraba el Paris Vintage Photobook, donde se habían juntado varios libreros que este año no estaban ni en el barco ni en el Palais, como Claude Lemaire, de L’Ascenseur Végétal de Burdeos, o Clément Kauter, del imprescindible Plac’Art,  Dirk K. Bakker, Zarbie Books, Ofr, y alguno más. Llegué solo a tiempo de saludar a Claude, con frustración o alivio… Un lugar lleno de deseo y peligro.

No habia acabado el día, y la galeria Temple, de Anna Planas y Pierre Hourquet   presentaba The Hobbyist, con Lotte Reimann haciendo lecturas de su libro Bis morgen im Nassen con experiencia virtual de la exposición de Winthertur.

  Y ya acabé el día en la galería -libreria In Between, de Luigi Clavareau, otro templo de la fotografía japonesa en París, donde había una fiesta con firmas de los nuevos libros de Koji Onaka, de Morten Andersen y de la gran Emi Anrakuji, con presencia del librero de Lisboa, estrenándose como editor, Rui Ribeiral. Precioso libro el de Emi, del que espero volver a hablar aquí.

  Conocí por fin a Colin Pantall, que llegó a Paris con cajas de su nuevo libro All quiet in the home front, para firmarlos en Polycopies, desde el stand del Tipi. Colin es un gran tipo, y es emocionante ver como habla de su relación padre-hija y lo que ha supuesto para el.

    Ya no quiero aburrir a nadie y solamente diré que el sábado volví al Grand Palais donde Kazuma Obara firmaba Exposure en su version editada por RM. Ya he hablado en el blog de este trabajo de Kazuma, siempre exquisito de sensibilidad y honradez, sobre el accidente de Chernobil. La nueva edición sigue teniendo la misma exigencia, tanto por parte del autor como por la de la editora.

    Todavia no he hablado de los premios de Aperture a mejor libro del año, que ha ganado la gran fotógrafa Indú Dayanita Singh, con Museum Bahvan, editado por Steidl. Caja ( hecha a mano ) de libros- leporello, museo portátil, precioso objeto de una artista que siempre ha valorado el libro en su trabajo. El premio a mejor primer libro fue, sin sorpresas, a Monsanto, de Mathieu Asselin, editado por Actes Sud y Verlag Kettler, un enorme e impresionante trabajo de investigación sobre las consecuencias del uso de los productos químicos del gigante agroalimentario Norteamericano, que se ha podido ver este verano en Arlés. Hay que resaltar la mención especial a La Grieta, de Carlos Spottorno, ( con guión de Guillermo Abril ) editado en España por Astiberri, mezcla de fotolibro y novela grafica, un híbrido dentro del mundo de la fotografía. New realities: Photography in the 19th Century ganó el premio al mejor catálogo, publicado por el Rijiskmuseum/Nai, Amsterdam,  una gran retrospectiva de los inventores de la fotografía, con una bonita cubierta homenaje a Anna Atkins. Todos premios merecidos y esperados…

    Ese sábado acabé el día con una cena organizada  por los editores de la Gould Collection, Russet Lederman, Laurence Vecten y Yoko Sawada, honrando la memoria de Christophe Crison, gran coleccionista y amante de la fotografía, el cine y la literatura. La Gould Collection reune a un gran fotógrafo con un autor literario, el segundo libro, It don’t mean a thing juntando a Saul Leiter con Paul Auster. Una gran reunión de photobooks freaks de muchos horizontes, hablar con el grande Brian Griffin y Delphine Bedel y conocer a Miho Kajioka, arigato !

      El domingo llovía. ¿Que mejor que ir a la BNF, biblioteca nacional de Francia? Llegar hasta su puerta fue largo y frío, aún bien acompañada, (verdad, Antonio Pérez Río ? ) pero la espera valía la pena, para ver la exposición Paysages Français, Una aventure photographique, enorme retrato de Francia en mas de mil fotografías y 160 fotógrafos, tanto franceses como internacionales, Koudelka, Basilico, Brotherus, Anne Immelé….  Ya no hubo tiempo para volver a Offprint antes del cierre…

    Si fui el lunes a la Fondation Vuitton a ver la exposición Being Modern: MoMa in Paris. La modernidad llegó a Nueva York venida de Europa, con las maletas llenas de obras maestras, si bien luego los Norteamericanos nos devolvieron su carga  bien digerida. Muy buena exposición la de Vuitton, con bastante fotografía también ( bonita serie de fotos anónimas, Atget, Walker Evans, Arbus, Cindy Sherman, Jeff Wall… ).

    Con la suerte de poder quedarme un poco más, pude escuchar también el lunes la conferencia que dieron Debi Cornwall y Lewis Bush en el Centro de la Universidad Columbia de Paris, con el titulo Photography in the age of Global Surveillance and Perpetual Wars Dos trabajos muy interesantes en los tiempos que corremos, el libro de Debi,  Welcome to Camp America: Inside Guantanamo Bay, estaba en la lista Aperture a mejor primer libro. Lewis Bush está a punto de publicar su nuevo trabajo, The shadows of the state: Mapping, spying, democracy.

      No pude ir a Le Bal, ni ver la exposición de Irving Penn, ni muchas cosas mas… Acabo este maratón con la exposición de Malick Sibidé, Mali Twist , en la Fondation Cartier. De Sibidé ya se ha escrito y visto mucho, yo he disfrutado de los vintage y de la banda sonora.

  Fin del twist à Paris… Vuelvo a casa con más libros de lo que debería, menos de lo que quisiera, y muchos buenos momentos. Más, si se puede, en noviembre del año que viene. Gracias por leer hasta aquí !

        EnregistrerEnregistrerEnregistrerEnregistrerEnregistrerEnregistrerEnregistrerEnregistrer

EnregistrerEnregistrerEnregistrerEnregistrer

20 de noviembre 2017. De vuelta de París. De vuelta de la locura de Paris Photo, os cuento aquí mi experiencia de una semana larga y tan corta a la vez, pasada corriendo cerca del Sena...

[ominous-feychild]

INCORRECT QUOTES:

RISING FROM MISFORTUNE

(Get it? Because it's kinda a crossover?)

Tián: (cheerfully and jokingly) “ah, looks like we won't be able to mansplain, manipulate, or manwhore our way outta this one, boys!”

Benji: (half-laughs; amusedly) “Seriously!? But I manwhore my way out of everything! What am I going to do now!?”

Tián: [spares a moment to give him an overdramatic wink and draw out a cartoonishly large sword] “manslaughter.”

The Rest of the Crew: [stunned silent]

Cricket: “I... somebody needs to stop this.” :'D

Flavie: (under her breath) “I don't know, that Tián guy is pretty hot...”

Cricket: (sharply, shocked) “What!?”

Flavie: (meets his eyes; deadpan) “What.”

Zarina: (evenly) “first of all, no.”

Cricket & Flavie: [look to her]

Zarina: (continues, not having stopped speaking) “Secondly...”

Zarina: [sighs heavily, putting her head in her hand]

Zarina: (defeatedly) “... I don't even know if I want to step in.”

Cricket: :'D

Flavie: [amused! But not complaining.]

Cricket: [sighs himself, but then shakes his head and pulls out his spellbook]

Cricket: (tiredly) “Don't worry about it, Captain. I'll take care this.”

Zarina: [just sighs again, hesitantly watching between her fingers—]

Cricket: [heading to Tián & Benji to put a stop to their shenanigans]

Flavie: (slightly obnoxiously) “Sooooooo...” ;DDDDD

Zarina: [hesitantly lifts her head from her hand to look up at her]

Flavie: [winks; amusedly) “You're staying up here to get a good view, too, huh?”

Zarina:

Zarina: [face flushes, but stands up straight—and crosses her arms, as she often does—to give Flavie a slight glare]

Zarina: (sharply) “Absolutely not!”

Flavie: [can't help a shit-eating grin]

Flavie: (teasingly) “oh, sure! So, tell me...”

Zarina: [narrows her eyes further in a much more obvious glare]

Flavie: (overdramatically, drawing out and savoring her words) “Is it Benji? Tián? Or, maybe even... Cricket?” >;DDDD

Zarina: [face only flashed in annoyance at Benji's name, disgusted at Tián's, but... goes empty and unreadable at Cricket's]

Flavie: (playfully) “OOOOOOOOO! The Captain and—”

Zarina: [scoffs, simultaneously turning away, heading to the stairs, and un-crossing an arm to wave it dismissively over her shoulder]

Zarina: (talking over Flavie) “Whatever you think is going on, don't say a word of it to Hugo.”

Zarina: [sets her hand on the stairs' handrail and twists on her heel to meet Flavie's eyes with a sharp, serious expression]

Zarina: (voice hard) “Or else. Understood?”

Flavie: [stunned—]

Flavie: [swallows slightly, but forces an awkward grin, stands at attention, and raises her hand in salute]

Flavie: (voice thick and uneven) “aye, aye, Captain. Wouldn't even dream of it.” ;'D

Zarina: [face softens—a flash of guilt crossing it—but quickly just turns away and hurries to help Cricket]

@honeybewrites @the-golden-comet @illarian-rambling @ashirisu @urnumber1star

@the-letterbox-archives @48lexr @aalinaaaaaa @thecomfywriter @an-indecisive-nerd

@seastarblue @leahnardo-da-veggie @world-of-iridensia

Banners from @saradika